The diagnostics innovator has bagged a further $100 million in damages, but the country’s patent system has put unnecessary hurdles in the way, argues representative John Desmarais.
Pharma companies in India are struggling to enforce compounds that are covered by both genus and subsequent species patents. While the latest case involved a series of injunctions being vacated, the patent community is still unsatisfied by the lack of concrete judgments on this issue.
The move is latest setback for the patentee in its dramatic written description dispute
17 October 2022
The European Commission has preliminarily found that the Israeli company has broken antitrust rules
11 October 2022
Docket Navigator shows that Amgen’s in-house legal team appeared on 78 of the 85 patent assertions in US district court since 2008
10 October 2022
The past two weeks have seen a flurry of patent-related activity at the US Supreme Court
07 October 2022
The Supreme Court's request for Solicitor General input increases the chances of a hearing on skinny-label controversies
06 October 2022
Ravgen is pursuing several large diagnostics companies in patent enforcement drive
04 October 2022
Following the firm’s recent $115 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband says a flurry of activity is underway in the market
03 October 2022
The Japanese company is leading the pack in trend of commercialising de-prioritised assets
30 September 2022
In the life sciences industry, patent protection for innovative medicinal products is pivotal to the commercial success of new drug products.
29 September 2022
Turkey’s recent compulsory licence decision shines a light on the questionable use of compulsory licence provisions around the world in relation to the pandemic. The creation of the covid vaccine has sparked discussions on IP rights and where the real regulatory focus should be.
28 September 2022
Unlock unlimited access to all IAM content
